Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Impedimed Limited ( (AU:IPD) ) just unveiled an announcement.
Impedimed Limited announced the cessation of certain securities, specifically 4,667,613 options and 413,284 performance rights, due to the lapse of conditional rights that were not met or became incapable of being satisfied. This cessation reflects a change in the company’s issued capital and may impact stakeholders by altering the company’s financial structure and market positioning.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
Impedimed Limited operates in the medical technology industry, focusing on products and services that provide non-invasive medical diagnostics. The company is known for its bioimpedance spectroscopy technology, which is used to assess and monitor fluid status and body composition, primarily for patients with conditions such as lymphedema and heart failure.
YTD Price Performance: -30.77%
Average Trading Volume: 2,188,125
Technical Sentiment Signal: Sell
Current Market Cap: A$72.99M
Learn more about IPD stock on TipRanks’ Stock Analysis page.